2124 POSTER Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

Triple Combination ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine ◽

5081 Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70973-5 ◽

2009 ◽

Vol 7 (2) ◽

pp. 285 ◽

Cited By ~ 2

Author(s):

R. Palumbo ◽

A. Bernardo ◽

M.R. Strada ◽

G. Poggi ◽

C. Teragni ◽

...

Keyword(s):

Breast Cancer ◽

Patient Compliance ◽

Metastatic Breast ◽

Line Treatment ◽

Triple Combination ◽

First Line ◽

Her2 Positive ◽

Oral Vinorelbine ◽

Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.1032 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 1032-1032 ◽

Cited By ~ 2

Author(s):

N. W. Peacock ◽

J. R. Infante ◽

D. A. Yardley ◽

H. A. Burris ◽

F. A. Greco ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Weekly Docetaxel ◽

Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2009.n.004 ◽

2009 ◽

Vol 9 (1) ◽

pp. 23-28 ◽

Cited By ~ 17

Author(s):

Jeffrey R. Infante ◽

Denise A. Yardley ◽

Howard A. Burris ◽

F. Anthony Greco ◽

Cindy P. Farley ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Weekly Docetaxel ◽

5071 POSTER Oral Vinorelbine in Combination With Capecitabine as a First Line Treatment in Patients (pts) With Metastatic Breast Cancer (MBC) Previously Treated With Anthracyclines ± Taxanes – Preliminary Results of a Multicentric Phase II Trial in Egypt

European Journal of Cancer ◽

10.1016/s0959-8049(11)71513-1 ◽

2011 ◽

Vol 47 ◽

pp. S351

Author(s):

A. Kandil ◽

E. Hamada ◽

M. Moawad ◽

L. Ezz El Arab ◽

H. Metwalli ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Oral Vinorelbine ◽

Previously Treated ◽

A phase II trial of dasatinib (D) in combination with trastuzumab (T) and paclitaxel (P) in the first line treatment of HER2 positive metastatic breast cancer (MBC) patients (pts): GEICAM/2010-04

Annals of Oncology ◽

10.1093/annonc/mdx365.002 ◽

2017 ◽

Vol 28 ◽

pp. v75 ◽

Cited By ~ 1

Author(s):

A. Ocana Fernandez ◽

M. Ruiz Borrego ◽

M. Gil Martin ◽

S. Antolin ◽

M. Atienza ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Epirubicin-Vinorelbine Intravenous Combination Followed by Oral Vinorelbine as First-Line Treatment in Metastatic Breast Cancer

Tumori Journal ◽

10.1177/030089160709300605 ◽

2007 ◽

Vol 93 (6) ◽

pp. 544-549 ◽

Cited By ~ 3

Author(s):

Antonio Ardizzoia ◽

Ilaria Colombo ◽

Monica Giordano ◽

Stefania Aglione ◽

Luciano Isa ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Oral Vinorelbine ◽

Trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(04)90842-7 ◽

2004 ◽

Vol 2 (3) ◽

pp. 125-126 ◽

Cited By ~ 20

Author(s):

J.M Extra ◽

F Cognetti ◽

D Maranichi ◽

R Snyder ◽

L Mauriac ◽

...

Keyword(s):

Breast Cancer ◽

Multicentre Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase II Trial with Gemcitabine, Paclitaxel and Bevacizumab for the First Line Treatment of Metastatic Breast Cancer.

10.1158/0008-5472.sabcs-09-6089 ◽

2009 ◽

Cited By ~ 2

Author(s):

A. Guardino ◽

M. Chen ◽

M. Levy ◽

C. Chen

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Letrozole in Combination with Trastuzumab Is Superior to Letrozole Monotherapy as First Line Treatment in Patients with Hormone-Receptor-Positive, HER2- Positive Metastatic Breast Cancer (MBC) – Results of theeLEcTRATrial.

10.1158/0008-5472.sabcs-09-4094 ◽

2009 ◽

Cited By ~ 6

Author(s):

J. Huober ◽

P. Fasching ◽

S. Paepke ◽

E. Kubista ◽

M. Barsoum ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Cited By ~ 1

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽